Sven has been a principal scientist of the core technology from the early days of the project. He graduated with a PhD in Molecular Microbiology from the ETH Zurich, co-authored many of the research publications on the technology, and is a co-inventor on some of the in-licensed patents. Sven has 20 years of hands-on research experience in microbiology and anti-infectives, with positions held at the Michigan State University, the Universities of Konstanz and Zurich, the Massachusetts Institute of Technology, and Visterra Inc. Throughout his career, Sven has significantly contributed to applied and translational science, mainly in drug discovery, on both biologics and small molecule therapeutics.
Anna has worked at several prestigious European universities and research institutes and holds a Ph.D. degree from the Medical University of Innsbruck. Anna tops more than a decade of academic experience with antibiotic targets with a solid exposure to applied clinical research, gained in both international contract research organizations (CROs) and in clinical-trial sponsor organizations. She has pushed forward excellence in investigational medicinal product and medical device development, clinical project management, quality management and regulatory interactions with national and supra-national competent authorities. Outside of her primary professional occupation, Anna has actively supported the development of educational content on therapeutic innovation for a broad patient-audience within a public-private partnership project of the European EUPATI consortium.
Marc has extensive experience in both academia and industry, having worked more than 20 years in R&D in the chemical and life-sciences. He holds a BSc from the University of Durham and a PhD in medical biochemistry from the University of Cambridge, UK. He was co-founder, Chief Scientific Officer and inventor of granted patents at a biotech startup company in the UK, where he learned the challenges and opportunities of entrepreneurship. Marc is also active in Swiss science policy as a member of the Board of Platform Biology of the Swiss Academy of Sciences (SCNAT), the Board of the Swiss Antibiotics Roundtable and President of the Advisory Board of the Swiss Young Academy, where his interests lie on role of innovation in the life sciences, science-communication and technology transfer.